SICK at a glance
IFRS figures for the SICK Group
| 2024 | 2023 | 2022 | 2021 | 2020 | |
Net sales (in millions of euros) | 1.736,8 | 1.962,8 | 2.189,8 | 1,964 | 1,700.2 |
| EBIT (in millions of euros) | 55,0 | 150,7 | 164,6 | 202.3 | 140.6 |
| Annual yield (in millions of euros) | 237,3 | 134,4 | 119,5 | 147.8 | 101.1 |
| Cash flow (in millions of euros) | 140,6 | 117,6 | 55,0 | 231.1 | 227.7 |
| Employees as of December 31 | 11.804 | 12.185 | 11.909 | 11,022 | 10,433 |
| R&D expenditure (in millions of euros) | 231,6 | 234,6 | 240,8 | 210.3 | 201.1 |
| Earnings per share (in EUR) | 9,05 | 5,12 | 4,56 | 5.64 | 3.86 |
Please note: In the fiscal year 2024, SICK agreed to a strategic partnership with Endress+Hauser for process automation. As a result, the accounting standard IFRS 5 must be applied to the previous fiscal year. This requires that the comparative values for the fiscal year 2023 be adjusted and thus are no longer comparable with previous years. The financial figures for the years 2023 and following are to be understood without the "Cleaner Industries" business, which will not be continued within SICK AG as part of the partnership from 2025 onwards.